Logo

Samsung Bioepis Presents Results of SB5 (biosimilar, adalimumab) in P-I and (PROPER) Study for Rheumatoid Arthritis and Other Inflammatory Diseases at EULAR 202

Share this
Samsung Bioepis Presents Results of SB5 (biosimilar, adalimumab) in P-I and (PROPER) Study for Rheumatoid Arthritis and Other Inflammatory Diseases at EULAR 202

Samsung Bioepis Presents Results of SB5 (biosimilar, adalimumab) in P-I and (PROPER) Study for Rheumatoid Arthritis and Other Inflammatory Diseases at EULAR 202

Shots:

  • The P-I study evaluates the new SB5 formulation (40mg/0.4 mL) vs the original SB5 formulation (40mg/0.8 mL) in male patients with RA & other inflammatory diseases. The results showed the clinical equivalence b/w 2 formulations, were well tolerated with similar safety profiles
  • The pan-EU real-world (PROPER) study evaluates Humira vs SB5 in 1000 patients with RA, axSpA, PsA, UC, or CD. Eligible patients had been transitioned to SB5 as part of routine treatment following 16wks. with reference ADL.
  • Results were recorded for 24wks. prior to the switch & 48wks. following the switch to SB5. The study showed that adalimumab therapy's effectiveness persisted on the biosimilar after 48wks. and the majority of patients opted to continue on SB

Ref: Samsung Bioepis | Image: Samsung Bioepis

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions